Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
PDE Inhibitor
PDE1-IN-3 is a selective inhibitor of human phosphodiesterase 1 (PDE1), known for its potential to modulate intracellular cyclic nucleotide levels. This compound also demonstrates inhibitory activity against PDE4D and PDE6AB, with IC50 values of 23.99 μM and 10 μM, respectively. PDE1-IN-3 is suitable for research applications focused on cardiovascular diseases, neuroprotection, and other conditions where cyclic nucleotide signaling plays a critical role. -
PDE III Inhibitor
WIN-63291 is a selective and orally active phosphodiesterase III (PDE III) inhibitor. It effectively increases intracellular cyclic AMP levels, which plays a critical role in cardiovascular function. This compound is primarily utilized in research applications aimed at investigating cardiovascular diseases and their associated pathways. -
AR Antagonist/PDE5 Inhibitor
ID11916 is an orally active antagonist of the androgen receptor (AR) and a phosphodiesterase 5 (PDE5) inhibitor. It effectively inhibits androgen binding to AR, prevents nuclear translocation, and suppresses androgen-dependent transcriptional activity. Additionally, ID11916 elevates intracellular cGMP levels and activates protein kinase G (PKG) through its inhibitory effects. This compound demonstrates significant anti-cancer activity against prostate cancer cell lines VCaP and 22Rv1, as well as in AR-positive breast cancer cell lines such as SK-BR-3, making it a valuable tool for cancer research. -
PDE Inhibitor
Menabitan dihydrochloride is a selective inhibitor of phosphodiesterase 9 (PDE 9), demonstrating potential as a non-opioid analgesic agent. This compound has been shown to effectively reduce intraocular pressure in rabbit models, making it valuable for research in ocular health and pain management. Its specificity for PDE 9 positions it as an important tool for studies investigating the role of cyclic nucleotides in various physiological processes. -
PDE4 Inhibitor
Davalomilast is a selective phosphodiesterase 4 (PDE4) inhibitor known for its anti-inflammatory properties. This compound is of particular interest in research on autoimmune diseases and dermatological conditions, where it may modulate inflammatory responses and provide therapeutic insights. Its mechanism suggests potential applications in alleviating symptoms associated with various inflammatory disorders. -
PDE3 Inhibitor
OPC-33540 is a highly selective and competitive inhibitor of phosphodiesterase 3 (PDE3), exhibiting IC50 values of 0.32 nM for PDE3A and 1.5 nM for PDE3B. This compound demonstrates significantly reduced activity against other phosphodiesterases, with IC50 values ranging from 42.9 μM to 100.8 μM for PDE1, PDE2, PDE4, PDE5, and PDE7. OPC-33540 effectively increases cAMP levels in platelets and inhibits thrombin-induced platelet aggregation, making it a valuable tool for antithrombotic research applications. -
PDE 10 Inhibitor
Gemlapodect is a potent inhibitor of phosphodiesterase 10A (PDE10A). This compound has been shown to modulate intracellular signaling pathways and is primarily used in researching schizophrenia. Its ability to prevent the degradation of cyclic nucleotides makes it a valuable tool for studying neuropsychiatric disorders and potential therapeutic interventions. -
PDE11 Inhibitor
PDE11-IN-1 is a selective inhibitor of phosphodiesterase 11 (PDE11), a key enzyme involved in the regulation of cyclic nucleotide signaling. This compound plays a crucial role in adrenal insufficiency research by modulating intracellular cAMP and cGMP levels, which can impact adrenal hormone synthesis and secretion. PDE11-IN-1 is a valuable tool for investigating the physiological and pathophysiological processes associated with adrenal function and related disorders. -
PDE Inhibitor
5,7-Diacetoxy-8-methoxyflavone is a potent phosphodiesterase (PDE) inhibitor with a mechanism of action targeting cAMP metabolism. This compound exhibits significant biological activity by enhancing cAMP levels, thereby influencing various cellular processes. It is primarily utilized in research applications focused on cell signaling, inflammation, and potential therapeutic interventions related to PDE modulation. -
PDE Inhibitor
ER21355 hydrochloride is a potent phosphodiesterase (PDE) inhibitor that enhances levels of cyclic AMP (cAMP) and cyclic GMP (cGMP) within cells. This action facilitates the relaxation of smooth muscle cells, making it a valuable candidate for research into therapeutic strategies for benign prostatic hyperplasia (BPH) and related conditions. ER21355 hydrochloride provides a useful tool for studies focused on the modulation of smooth muscle relaxation and its implications in prostatic disorders. -
PDE-III Inhibitor
Meribendan is a potent phosphodiesterase III (PDE-III) inhibitor. It enhances intracellular cyclic adenosine monophosphate (cAMP) levels, promoting cardiac contractility and vasodilation. This compound is primarily used in cardiovascular research, providing insights into heart failure mechanisms and potential therapeutic strategies. -
PDE8B Inhibitor
PDE8B-IN-1 hydrochloride is a potent and selective inhibitor of phosphodiesterase type 8B (PDE8B) with an IC50 value of 1.5 nM. This compound is valuable for research focused on the modulation of intracellular cAMP levels, which is relevant in the study of diabetes and related metabolic disorders. PDE8B-IN-1 hydrochloride provides a useful tool for investigating the role of PDE8B in cellular signaling pathways and potential therapeutic strategies. -
PDE5 Inhibitor
Thioquinapiperifil is a potent, selective, and non-competitive inhibitor of phosphodiesterase-5 (PDE-5), with an IC50 of 0.074 nM. This compound is primarily utilized in research focusing on sexual enhancement and the modulation of erectile function. Its high specificity and efficacy make it a valuable tool for investigating PDE5-related pathways and potential therapeutic applications in sexual health. -
PDEδ Inhibitor
Deltazinone 1 is a selective phosphodiesterase δ (PDEδ) inhibitor with a KD value of 8 nM, targeting the PDEδ-Ras interaction. It demonstrates a dose-dependent inhibitory effect on the proliferation of oncogenic KRas-dependent cell lines, making it a valuable compound for studying KRas signaling pathways and potential therapeutic interventions in cancer research. -
PDE4 Inhibitor
PDE4-IN-34 is a selective phosphodiesterase 4 (PDE4) inhibitor, demonstrating IC50 values of 19 pM and 14 pM for PDE4B1 and PDE4D2, respectively. This compound shows weak inhibitory activity against PDE8A1 (IC50 of 4.092 μM) and exhibits significant selectivity over other PDE subtypes (IC50 > 10 μM). PDE4-IN-34 effectively improves pulmonary function, reduces inflammatory responses, and mitigates lung tissue damage in rat models of chronic obstructive pulmonary disease induced by cigarette smoke and LPS. It serves as a valuable tool for research into PDE4-related pathways in pulmonary disorders. -
PDE11A4 Inhibitor
PDE11A4-IN-1 is a selective inhibitor of the phosphodiesterase 11A4 (PDE11A4) enzyme, exhibiting an IC50 of 12 nM. This compound demonstrates strong selectivity for PDE11A4 compared to other phosphodiesterases including PDE1, PDE2, PDE7, PDE8, and PDE9. It is suitable for studies investigating the role of PDE11A4 in various biological processes and potential therapeutic applications in conditions influenced by cyclic nucleotide signaling. -
PDE3/4 Inhibitor
PDE3/4-IN-3 is a potent dual inhibitor of phosphodiesterase 3 and 4, exhibiting IC50 values of 0.17 nM for PDE3A and ≤50 nM for PDE4B2. This compound effectively reduces methacholine-induced bronchoconstriction in guinea pigs, demonstrating its potential in respiratory research. PDE3/4-IN-3 is valuable for investigating therapeutic strategies in chronic obstructive pulmonary disease (COPD) and asthma. -
Phosphodiesterase (PDE) Inhibitor
RA642 is a selective phosphodiesterase (PDE) inhibitor that enhances arterial blood pressure and promotes vasodilation. This compound demonstrates significant biological activity by improving cerebral blood flow and reducing both cerebrovascular and peripheral resistance. It exhibits a relaxant effect on smooth muscle, akin to that of papaverine, making it a valuable tool for studying cardiovascular dynamics and smooth muscle physiology in research settings. -
Phosphodiesterase (PDE) Inhibitor
ATX inhibitor 7 is a selective inhibitor of autotaxin, a lysophospholipase that catalyzes the production of lysophosphatidic acid (LPA) from lysophosphatidylcholine. This compound demonstrates significant oral bioavailability, making it a valuable tool for investigations into the role of LPA signaling in various physiological and pathological processes. ATX inhibitor 7 is suitable for research applications related to cancer, fibrosis, and neurodegenerative diseases, where modulation of autotaxin activity may offer therapeutic benefits. -
PDE5 Inhibitor
T-1032 free base is a highly selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 1.0 nM. It demonstrates a significant relaxant effect on isolated rabbit corpus cavernosum. T-1032 free base is primarily utilized in research focused on erectile dysfunction and related vascular disorders. -
PDE Inhibitor
Imazodan hydrochloride is a selective phosphodiesterase III (PDE III) inhibitor that enhances myocardial contractility by preventing the degradation of cyclic adenosine monophosphate (cAMP). This compound improves cardiac contractile function and serves as a peripheral vasodilator. Imazodan hydrochloride is relevant for research applications involving cardiovascular conditions and the modulation of heart function. -
PDE Inhibitor
Isopedicin is a potent phosphodiesterase (PDE) inhibitor that effectively reduces superoxide anion (O2•-) production in formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)-activated cells. By inhibiting PDE activity, Isopedicin enhances cyclic AMP (cAMP) formation and promotes protein kinase A (PKA) activity, thereby influencing various intracellular signaling pathways. This compound is suitable for research applications investigating oxidative stress and signaling mechanisms in immune responses. -
PDE2A Inhibitor
PDE2A-IN-2 is a selective inhibitor of phosphodiesterase type 2A (PDE2A) with a Ki value of 5.49 nM, demonstrating over 100-fold selectivity against other PDE isoforms. This compound serves as a radiolabeled PET tracer, facilitating brain imaging in patients with neurodegenerative diseases by eliciting a signal specifically in PDE2A-rich regions. Its application in neurodegenerative disease research highlights its potential in studying PDE2A's role in pathophysiology. -
PDE5 Inhibitor
(R)-Xanthoanthrafil is a selective phosphodiesterase-5 (PDE5) inhibitor. By increasing cyclic guanosine monophosphate (cGMP) levels, it promotes smooth muscle relaxation, facilitating penile erection. This compound is valuable for research applications related to erectile dysfunction and the physiological mechanisms governing this condition. -
PDE4 Inhibitor
Z21090 is a selective inhibitor of phosphodiesterase-4 (PDE4), exhibiting an IC50 value of 37.4 nM and demonstrating oral bioavailability. This compound is significant for studies related to alcohol-related diseases and offers potential therapeutic insights into inflammatory processes and neurodegenerative conditions associated with PDE4 activity. Researchers may utilize Z21090 to explore its effects on cyclic AMP signaling pathways and related biological mechanisms. -
PDE4 Inhibitor
LT-104A is a selective phosphodiesterase 4 (PDE4) inhibitor that effectively elevates intracellular cyclic AMP (cAMP) levels, exhibiting an EC50 of 1.9 μM and inhibiting PDE4D3 activity with an IC50 of 9.3 μM. By activating the cAMP-PKA-CREB anti-inflammatory signaling pathway, LT-104A suppresses expression of NF-κB-related genes such as Il1b and Nos2. This compound is valuable for research focused on inflammation-related diseases and therapeutic interventions aimed at modulating inflammatory responses. -
PDE Inhibitor
Menabitan is a selective inhibitor of phosphodiesterase 9 (PDE 9), exhibiting non-opioid analgesic properties. This compound has demonstrated efficacy in lowering intraocular pressure in rabbit models, making it a valuable tool for research in ophthalmology and pain management. Its inhibition of PDE 9 underlines its potential in developing therapeutic strategies for conditions associated with elevated intraocular pressure. -
PDE5 Inhibitor
BMS-341400 is a potent, orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 0.3 nM. By inhibiting PDE5, BMS-341400 effectively prevents the breakdown of cyclic guanosine monophosphate (cGMP), facilitating nitric oxide (NO)-induced smooth muscle relaxation in the corpus cavernosum, which promotes erectile function. This compound is primarily utilized in the study of erectile dysfunction and related pathways in sexual health research. -
PDE III Inhibitor
CK-2289 is a selective inhibitor of type III cyclic 3',5'-adenosine monophosphate phosphodiesterase (PDE III). This compound demonstrates significant efficacy in inhibiting platelet aggregation and lowering mean arterial blood pressure, making it a valuable tool in cardiovascular research. CK-2289 is particularly relevant for studies focused on cardiovascular diseases, including congestive heart failure. -
Phosphodiesterase (PDE) Inhibitor
Parogrelil hydrochloride is a selective phosphodiesterase (PDE) inhibitor, primarily targeting PDE3. It demonstrates significant biological activity by inhibiting human platelet aggregation in vitro and reducing aortic contraction in rat models. Research indicates that Parogrelil hydrochloride effectively improves walking distance and increases plantar surface temperature in the rat femoral artery ligation model, exhibiting superior efficacy compared to cilostazol. This compound is valuable for studies focused on cardiovascular health and peripheral artery disease. -
PDE6δ-KRas Inhibitor
Deltasonamide 1 TFA is a potent inhibitor of the PDE6δ-KRas interaction, exhibiting a binding affinity with a KD of 203 pM. This compound is valuable in research focused on cancer biology, particularly in the study of tumor progression and metastasis. Its ability to disrupt the PDE6δ-KRas axis makes it a useful tool for investigating the underlying mechanisms of KRas-driven malignancies. -
PDE5A Inhibitor
PF-03049423 free base is a selective inhibitor of phosphodiesterase-5A (PDE5A), exhibiting an IC50 of approximately 0.2 nM in both rat and human platelet enzymes. This compound demonstrates significant potential for research applications focused on acute ischemic stroke, where modulation of PDE5A activity may impact downstream signaling pathways and cellular responses. Researchers can utilize PF-03049423 to explore its effects on vascular function and neuroprotection in ischemic conditions. -
PDE4 Inhibitor
PDE4-IN-12 is a potent pan-PDE4 inhibitor that demonstrates IC50 values of 3.5 nM for PDE4 and 15 nM for PDE7, with selectivity indices of 2.71 and 4.27, respectively. This compound is well-tolerated and is suitable for research applications in the study of inflammatory bowel diseases (IBDs) and related inflammatory conditions. Its strong inhibitory activity on phosphodiesterase enzymes makes it a valuable tool for investigating therapeutic strategies in inflammatory disorders. -
Phosphodiesterase (PDE) Inhibitor
Reproterol hydrochloride is a selective phosphodiesterase (PDE) inhibitor that also acts as a dual-acting beta2-adrenoceptor agonist. It effectively stimulates cyclic AMP (cAMP) production in human monocytes, demonstrating potential for enhanced airway function. Additionally, Reproterol hydrochloride exhibits significant inhibition of leukotriene B4 (LTB4) production, suggesting anti-inflammatory properties that may be beneficial in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). -
PDE V Inhibitor
FR-229934 is a phosphodiesterase type V (PDE V) inhibitor that demonstrates potential therapeutic effects in the treatment of pulmonary arterial hypertension and erectile dysfunction. By inhibiting PDE V, FR-229934 increases intracellular cAMP levels, leading to vasodilation and improved blood flow. This compound is valuable for research applications focused on cardiovascular diseases and sexual health disorders. -
Phosphodiesterase (PDE) Inhibitor
Gisadenafil is a selective, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM. By inhibiting PDE5, it effectively prevents the degradation of cyclic guanosine monophosphate (cGMP), leading to increased intracellular cGMP levels. This mechanism has potential applications in the treatment of erectile dysfunction and pulmonary hypertension, facilitating improved vasodilation and blood flow. -
PDE9 Inhibitor
(R)-Irsenontrine is a potent inhibitor of phosphodiesterase 9 (PDE9) with an IC50 value of 0.041 μM. This compound plays a significant role in modulating cGMP levels and is particularly relevant for research focused on neurological diseases. Its ability to selectively inhibit PDE9 makes it a valuable tool for investigations into cognitive function and related pathological conditions. -
PDE5 Inhibitor
PDE5-IN-9 is a potent phosphodiesterase type 5 (PDE5) inhibitor with an IC50 of 11.2 μM. This compound selectively interacts with key amino acid residues, including Gln 817, Tyr 612, and Ala 767, enhancing its efficacy. PDE5-IN-9 is primarily utilized in research focused on cardiovascular diseases, providing a valuable tool for studying related pathophysiological mechanisms. -
Phosphodiesterase (PDE) Inhibitor
PDE5-IN-8 is a selective phosphodiesterase type 5 (PDE5) inhibitor. This compound enhances intracellular levels of cyclic GMP, leading to vasodilation and increased blood flow. PDE5-IN-8 is primarily utilized in research exploring cardiovascular diseases, erectile dysfunction, and related therapeutic areas, highlighting its potential in modulating nitric oxide signaling pathways. -
PDE4B Inhibitor
HY-072808 is a selective inhibitor of phosphodiesterase-4B (PDE4B), which plays a critical role in modulating cyclic nucleotide signaling pathways. This compound demonstrates potential biological activity in reducing inflammation and may be utilized in research to investigate therapeutic approaches for atopic dermatitis. Its targeted inhibition of PDE4B makes it a valuable tool for studying the effects of cyclic nucleotide modulation in various cellular contexts. -
PDE4 Inhibitor
PDE4-IN-29 is a selective phosphodiesterase 4 (PDE4) inhibitor, with sub-nanomolar potency against PDE4D3, exhibiting IC50 values of less than 5 nM. By inhibiting the degradation of cyclic adenosine monophosphate (cAMP), PDE4-IN-29 effectively elevates intracellular cAMP levels, leading to a reduction in inflammatory cytokine release, including TNF-α. This compound is of great interest for investigating inflammatory diseases such as psoriasis, atopic dermatitis, and chronic obstructive pulmonary disease. -
PDE10A Inhibitor
ASP9436 is a potent and orally available inhibitor of phosphodiesterase 10A (PDE10A), exhibiting an IC50 of 8 nM against human PDE10A. This compound effectively reduces locomotor activity in mouse models of hyperactivity and improves visual recognition memory deficits in neonatal mice. ASP9436 is valuable for research focused on understanding and potentially treating schizophrenia. -
PDE4 Inhibitor
Tofimilast is a selective inhibitor of Phosphodiesterase 4 (PDE4) with an IC50 of 0.14 μM. By blocking PDE4 activity, Tofimilast elevates intracellular cyclic adenosine monophosphate (cAMP) levels, contributing to its anti-inflammatory properties. This reagent is valuable for research applications aimed at exploring inflammatory pathways and potential therapeutic interventions in respiratory and autoimmune conditions. -
PDE4D Inhibitor
GEBR-7b is a selective inhibitor of phosphodiesterase 4D (PDE4D), exhibiting an IC50 of 0.67 μM. This compound enhances hippocampal cyclic adenosine monophosphate (cAMP) levels without affecting amyloid-beta (Aβ) concentrations in rodent models. GEBR-7b has demonstrated efficacy in improving spatial memory, making it suitable for investigating cognitive deficits and the underlying mechanisms of neurodegenerative diseases. -
cGMP-PDE Inhibitor
DPN-205-734 is a selective cGMP-PDE inhibitor that exerts positive inotropic effects on cardiac muscle cells. This compound has been shown to reduce blood pressure and overall peripheral resistance in various animal models, indicating its potential for cardiovascular effects. DPN-205-734 is suitable for research applications focused on cardiovascular and cerebrovascular diseases, including heart failure and related conditions. -
PDE4D2 Inhibitor
Norbraylin is a natural prenylated coumarin that serves as an inhibitor of the phosphodiesterase 4D2 (PDE4D2) enzyme, exhibiting an IC50 value of 7.15 µM. This compound is utilized in research to explore the modulation of intracellular signaling pathways mediated by cyclic adenosine monophosphate (cAMP). Its activity makes it a valuable tool for studies related to inflammation, neurobiology, and various other fields of biomedical research. -
PDE5 Inhibitor
T-1032 is a selective phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 value of 1.0 nM. This compound demonstrates a relaxant effect on isolated rabbit corpus cavernosum, making it a valuable tool for investigating mechanisms involved in erectile dysfunction. T-1032 is suitable for research applications focused on penile vascular physiology and therapies for erectile dysfunction. -
PDE4 Inhibitor
PDE4-IN-33 is a selective inhibitor of phosphodiesterase 4 (PDE4), an enzyme involved in the degradation of cyclic AMP. This compound effectively reduces uric acid levels, making it a valuable tool for studying conditions associated with hyperuricemia and gout. Its role in modulating inflammatory responses highlights its potential in therapeutic research for these metabolic disorders. -
PDE3/PDE4 Inhibitor
ORG-20241 is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). This compound exhibits a significant bronchodilator effect and effectively prevents allergen-induced airway hyperresponsiveness. Additionally, ORG-20241 significantly inhibits eosinophil infiltration at elevated concentrations. It serves as a valuable tool for research focused on asthma and related respiratory conditions. -
PDE10A Inhibitor
PDE10A-IN-1 is a potent inhibitor of phosphodiesterase 10A (PDE10A), exhibiting an IC50 of 250 nM. This compound effectively crosses the blood-brain barrier, making it valuable for studies related to neurological disorders, particularly schizophrenia. Research applications include investigating the role of PDE10A in neuropsychiatric conditions and exploring therapeutic avenues for treatment.
